secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2026-10-21T11:36:13+00:00
Accession:  0001628280-26-066601
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Abbott Q3 2026 sales up 14.5% reported, 7.0% comparable; adjusted EPS $1.42; FY guidance tightened to $5.50-$5.55
--------------------------------------------------------------------------------

- Total company third-quarter sales were $13.01 billion, up 14.5% reported and 7.0% comparable, with U.S. sales up 28.0% to $5.50 billion.
- GAAP diluted EPS was $0.53 versus adjusted diluted EPS of $1.42; full-year 2026 adjusted EPS guidance reaffirmed at midpoint and narrowed to $5.50-$5.55.
- Diagnostics sales jumped 46.7% reported to $3.31 billion, driven by the March 23, 2026 Exact Sciences acquisition and 13.8% comparable Cancer Diagnostics growth.
- Medical Devices sales rose 6.9% to $5.83 billion, led by 15.0% growth in Electrophysiology; Diabetes Care CGM sales grew 7.3% reported.
- Abbott cited FDA approval of Libre Duo, CE Mark for Amulet 360, FDA approval of TactiFlex Duo and launch of SimpleScreen CRC; Q4 adjusted EPS guided to $1.62-$1.67.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828026066601/0001628280-26-066601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828026066601/abt-20261021.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-066601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer